Michael Rieger

Assistant Professor (W2)

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael Rieger is an Assistant Professor (W2) at Goethe-University Frankfurt, University Hospital, Germany. His research areas encompass hematopoietic stem cells, colorectal cancer, and immunotherapy, with recent publications highlighting topics such as CRISPR/Cas9 technology, epithelial-to-mesenchymal transition, and the modulation of megakaryopoiesis. His work is focused on integrating molecular biology and clinical applications to advance therapeutic strategies.

Articles (20)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (17)

Jiaoyan Han

Goethe University Frankfurt

GERMANY

Michael Rieger

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

FACS-Based Assessment of Human Hematopoietic Stem and Progenitor Cells

Frosted DNA: β‐Galactosidase Control of Oligonucleotide Activity

Development of a Potent and Selective G2A (GPR132) Agonist

Transglutaminase 2 promotes epithelial-to-mesenchymal transition by regulating the expression of matrix metalloproteinase 7 in colorectal cancer cells via the MEK/ERK signaling pathway.

CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.

RUNX1 interacts with lncRNA SMANTIS to regulate monocytic cell functions.

Intracranial injection of NK cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

Wnt/β-Catenin-Signaling Modulates Megakaryopoiesis at the Megakaryocyte-Erythrocyte Progenitor Stage in the Hematopoietic System

Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.

Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target.

Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD

HIV-1 Infection of Long-Lived Hematopoietic Precursors In Vitro and In Vivo

Editorial commentary: A heartbreaking relationship: Clonal hematopoiesis and heart failure

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma

GPR182 is an endothelium-specific atypical chemokine receptor that maintains hematopoietic stem cell homeostasis

Full spectrum of clonal haematopoiesis‐driver mutations in chronic heart failure and their associations with mortality

Clonal Hematopoiesis–Driver DNMT3A Mutations Alter Immune Cells in Heart Failure

Single-cell RNA-sequencing reveals profound changes in circulating immune cells in patients with heart failure

Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations

Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients

Collaborators (17)

Jiaoyan Han

Halvard Bonig

Ingrid Fleming

Soni Savai Pullamsetti

Winfried Wels

David John

Ralf Duerr

Timm Schroeder

Haaglim Cho

Marcus Fruttiger

Julius Enssle

Norbert Weissmann

Ralph Schermuly

Philip Gribbon

Rolf Marschalek

Stefan Hadzic

M.C. Burger

Make your next move.